Clinical trials: Overweight or Obese
Overweight, Obesity
A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
This study will look at the change in teenagers' body weight from the start to the end of the study. This is to compare the effect on body weight in teenagers taking semaglutide (a new medicine) and teenagers taking "dummy"…
- Trial name
- NCT04102189
- Testing
- Semaglutide
- Where
- 51 sites in United States, Austria and 6 more
- Volunteers
- 201 people
- Sponsor
- Novo Nordisk A/S
Endometrial Carcinoma, Obesity
Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
To assess the feasibility of an expedited referral process for the obese endometrial cancer or EIN patient from her gynecologic oncologist to the Brigham Center for Metabolic and Bariatric Surgery (CMBS) in order to undergo…
- Conditions
- Endometrial Carcinoma, Obesity, EIN, Endometrial Intraepithelial Neoplasia
- Trial name
- NCT04839614
- Testing
- CONCURRENT LAPAROSCOPIC HYSTERECTOMY AND WEIGHT LOSS SURGERY-Referral
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Polycystic Ovary Syndrome
Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy
Oral contraceptives are known to improve menstrual cycles and symptoms in PCOS, however may increase cholesterol. Metformin, a drug to improve insulin resistance, may benefit metabolic state.
- Trial name
- NCT00283816
- Testing
- Metformin, Oral Contraceptive Pill, Lifestyle Management Program
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Alcohol Use Disorder, Obesity and Overweight
Tirzepatide for Alcohol Use Disorder
The objective of this Phase 2 randomized controlled trial is to evaluate the effects of weekly tirzepatide (vs. placebo) on alcohol consumption and cardiometabolic outcomes in adults with alcohol use disorder and overweight or…
- Conditions
- Alcohol Use Disorder, Obesity and Overweight, Alcohol
- Trial name
- NCT06994338
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Southern California
Obesity, Obesity, Morbid
Biological Sample Repository for Gastrointestinal Disorders
The goal of this observational study has the purpose of collecting biological samples from obese patients undergoing evaluation for weight loss by means of medical or endoscopic therapies; and of post bariatric surgery patients…
- Conditions
- Obesity, Obesity, Morbid, Obesity, Primary, Gastro-Intestinal Disorder
- Trial name
- NCT05874726
- Testing
- Blood Collection, Urine Collection, Tissue Sample Collection
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Pichamol Jirapinyo, MD, MPH
Obesity
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with…
- Trial name
- GZBF (NCT07467447)
- Testing
- Retatrutide (LY3437943), Standardized diet and physical activity counseling throughout the study.
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Hudson Biotech
Obesity
Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
This study evaluated the safety of VTX3232 administered alone or in combination with semaglutide in participants with obesity. Approximately 160 participants were randomized to receive VTX3232 30 mg, placebo, VTX3232 30 mg in…
- Trial name
- NCT06771115
- Testing
- VTX3232 30 mg, VTX3232 30 mg in combination with semaglutide
- Where
- 14 sites in United States
- Volunteers
- 175 people
- Sponsor
- Zomagen Biosciences Ltd.
Obesity
Effect of a Unique Web-based Behaviour Change Program on Weight Loss and Cardiovascular Risk Factors
Web- or internet-based programs have the potential to induce and, possibly, help to sustain, significant lifestyle modification.
- Trial name
- NCT01472276
- Testing
- Web-based program
- Where
- United Kingdom
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Queen's University, Belfast
Morbid Obesity, Hypertension
Prevention of Coronary Heart Disease in Morbidly Obese Patients
The changes in risks of developing coronary heart disease in patients with morbid obesity after different weight loss interventions have not been extensively studied.
- Conditions
- Morbid Obesity, Hypertension, Type 2 DM, Obstructive Sleep Apnea
- Trial name
- SphCor (NCT00626964)
- Testing
- Bariatric Surgery, Conservative Treatment:
- Where
- Norway
- Volunteers
- 200 people
- Sponsor
- The Hospital of Vestfold
CHD, Overweight or Obese
Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial
Coronary Heart Disease (CHD) is an ischemic heart disease caused by coronary atherosclerosis, and it is the leading cause of death from cardiovascular diseases worldwide.
- Trial name
- LIGHT-CHD (NCT07514611)
- Testing
- dietary regulation and structured exercise training
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Guangdong Provincial People's Hospital
Overweight and Obesity
Study of the Intestinal Microbiota During a Real Life Dietary Intervention in Subjects With Overweight or Obesity
Worldwide, 13% of the population had obesity in 2016 and overweight and obesity are recognized as the fifth leading risk factor for death (roughly 5 million deaths per year).
- Trial name
- GUTINSIDE (NCT04822948)
- Where
- France
- Volunteers
- 1,855 people
- Sponsor
- Integrative Phenomics
Bone Diseases, Obesity
Stereophotogrammetry of the Torso in Healthy Individuals and Patients With Scoliosis, Chest Wall Deformations, or Obesity
Background: Stereophotogrammetry (SP) uses four sets of digital cameras to generate a three-dimensional computer image. Unlike other types of evaluations which require radiation, SP only uses computer images to learn more about…
- Conditions
- Bone Diseases, Obesity, Healthy Volunteers
- Trial name
- NCT01352949
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Obesity, Overweight
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2…
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- AMPLIFY-2 (NCT07881458)
- Testing
- eloralintide and tirzepatide, Tirzepatide
- Where
- 75 sites in United States, Brazil and 8 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Overweight or Obesity
A Study of IBI3032 in Chinese Participants With Overweight or Obesity
This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of IBI3032 in participants with…
- Trial name
- NCT07170319
- Testing
- IBI3032
- Where
- China
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
Overweight, Obesity
A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Overweight or Obesity, Compared to a Low-calorie Diet or Placebo
The purpose of this clinical study is to evaluate how NNC0487-0111 affects the amount of energy the body uses in people living with obesity or overweight following weight loss.
- Trial name
- NCT07757087
- Testing
- NNC0487-0111, LED
- Where
- 2 sites in Denmark, Netherlands
- Volunteers
- 120 people
- Sponsor
- Novo Nordisk A/S
Obesity & Overweight
A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or…
- Trial name
- NCT07652047
- Testing
- CX11
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Corxel Pharmaceuticals
Overweight, Obesity
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities.
- Trial name
- NCT06023095
- Testing
- LY3502970
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Metabolic Syndrome, Obesity
Effects of Alpha Lipoic Acid Supplementation on Metabolic Syndrome Markers in Young Overweight or Obese Males
Eight weeks supplementation of alpha lipoic acid (known superantioxidant already produced by the body) will significantly improve metabolic syndrome markers (e.g., excess body weight, blood pressure, glucose, insulin, blood…
- Trial name
- ALA (NCT03342599)
- Testing
- Alpha Lipoic Acid Supplement
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of La Verne
Overweight, Obesity
A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity
The study will look at how two different forms of semaglutide reach and stay in the blood after injection. None of the two forms of semaglutide have been approved by the authorities to treat obesity.
- Trial name
- NCT04012255
- Testing
- Semaglutide (administered by DV3396 pen), Semaglutide (administered by PDS290 pen)
- Where
- 2 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Novo Nordisk A/S
Obesity
Transoral Gastric Volume Reduction as an Intervention for Weight Management
The purpose of this study is to evaluate the safety, technical feasibility, and initial effectiveness (i.e., weight loss primarily measured as percent excess weight loss) of TGVR performed using the Bard RESTORe Suturing System
- Trial name
- TRIM (NCT00679848)
- Testing
- RS2 (RESTORe Suturing System)
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- C. R. Bard